“COPD Navigator” – an innovative tool for doctor and patient
https://doi.org/10.18093/0869-0189-2025-35-1-86-94
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases in the world. Correct treatment of this disease shall account for many additional factors, which can be difficult for primary care physicians. In 2023, the International Primary Care Respiratory Group (IPCRG) developed a new tool for primary care physicians – the COPD “Wheel” that allows for determining the treatment tactics quickly and consulting COPD patients about the main causes and consequences of the disease. The aim of the work was to evaluate whether the innovative tool ensures the integration of physician and patient efforts in achieving COPD control. Conclusion. The COPD Wheel tool ensures timely prescription of drugs suitable for a specific clinical case, as well as significantly improves the patient’s adherence to therapy. As a result, patients with COPD should be expected to have improved quality of life and prognosis.
About the Authors
A. V. Budnevsky
Federal State Budgetary Educational Institution of Higher Education “N.N.Burdenko Voronezh State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Andrey V. Budnevsky, Doctor of Medicine, Professor, Honored Inventor of the Russian Federation, Head of the Department of Faculty Therapy
ul. Studencheskaya 10, Voronezh, 394622, tel.: (473) 263-81-30
Competing Interests:
The authors report that there is no conflict of interest.
S. N. Avdeev
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Sergey N. Avdeev, Doctor of Medicine, Professor, Academician of Russian Academy of Sciences, Head of the Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine; Chief Freelance Pulmonologist of the Ministry of Health of the Russian Federation; Director of the National Medical Research Center for Pulmonology
ul. Trubetskaya 8, build. 2, Moscow, 119991, tel.: (495) 708-35-76
Competing Interests:
The authors report that there is no conflict of interest.
E. S. Ovsyannikov
Federal State Budgetary Educational Institution of Higher Education “N.N.Burdenko Voronezh State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Evgeniy S. Ovsyannikov, Doctor of Medicine, Professor, Department of Faculty Therapy
ul. Studencheskaya 10, Voronezh, 394622, tel.: (473) 263-81-30
Competing Interests:
The authors report that there is no conflict of interest.
S N. Feigelman
Federal State Budgetary Educational Institution of Higher Education “N.N.Burdenko Voronezh State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Sofia N. Feigelman, Assistant, Department of Faculty Therapy
ul. Studencheskaya 10, Voronezh, 394622, tel.: (473) 263-81-30
Competing Interests:
The authors report that there is no conflict of interest.
References
1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2025 Report. Available at: https://goldcopd.org/2025-gold-report/ [Accessed: December 12, 2024].
2. Ministry of Health of the Russian Federation. [Clinical recommendations. Chronic obstructive pulmonary disease]. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/603_3 [Accessed: December 20, 2024] (in Russian).
3. Effing T.W., Vercoulen J.H., Bourbeau J. et al. Definition of a COPD self-management intervention: International Expert Group consensus. Eur. Respir. J. 2016; 48 (1): 46–54. DOI: 10.1183/13993003.00025-2016.
4. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Chronic obstructive pulmonary disease: federal clinical guidelines for diagnosis and treatment]. Pul'monologiya. 2022; 32(3): 356–392. DOI: 10.18093/0869-0189-2022-32-3-356-392 (in Russian).
5. Soriano J.B., Visick G.T., Muellerova H. et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128 (4): 2099–2107. DOI: 10.1378/chest.128.4.2099.
6. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245–1257. DOI: 10.1183/09031936.00133805.
7. Fabbri L.M., Luppi F., Beghé B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31 (1): 204–212. DOI: 10.1183/09031936.00114307.
8. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2024 Report. Available at: https://goldcopd.org/2024-gold-report/ [Accessed: December 26, 2024].
9. Yaltonskiy V., Yaltonskaya A., Sirota N., Moskovchenko D. [Psychometric characteristics of the Russian-language version of the short questionnaire on disease perception]. Psikhologicheskie issledovaniya. 2017; 10 (51): 1–14. DOI: 10.54359/ps.v10i51.407 (in Russian).
10. World Health Organization. Technical package for cardiovascular disease management in primary health care. Healthy-lifestyle counselling. Geneva: World Health Organization; 2018. Available at: https://iris.who.int/bitstream/handle/10665/260422/WHO-NMH-NVI18.1-eng.pdf;jsessionid=32900CB2DAF29876AA8FD97FCC5D2710?sequence=1 [Accessed: December 12, 2024].
11. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648. DOI: 10.1136/bmj.1.6077.1645.
12. IPCRG. Henrichsen S.H. Desktop Helper No.4 – Helping patients quit tobacco. 3rd edn. 2019. Available at: https://www.ipcrg.org/desktophelpers/desktop-helper-no-4-helping-patients-quit-tobacco-3rd-edition [Accessed: December 12, 2024].
13. IPCRG. Tsiligianni I., Williams S. Desktop helper No.12 – COPD and mental health: holistic and practical guidance for primary care. 2022. Available at: https://www.ipcrg.org/dth12 [Accessed: December 12, 2024].
14. Pollok J., van Agteren J.E., Carson-Chahhoud K.V. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2018; 12 (12): CD012346. DOI: 10.1002/14651858.CD012346.pub2.
15. Tsiligianni I., Kocks J., Tzanakis N. et al. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim. Care Respir. J. 2011; 20 (3): 257–268. DOI: 10.4104/pcrj.2011.00029.
16. Spathis A., Booth S., Moffat C. et al. The breathing, thinking, functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim. Care Respir. Med. 2017; 27 (1): 27. DOI: 10.1038/s41533-017-0024-z.
17. Berlin I., Covey L.S. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits. Addiction. 2006; 101 (12): 1814–1821. DOI: 10.1111/j.1360-0443.2006.01616.x.
18. Ho S.Y., Alnashri N., Rohde D. et al. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with chronic respiratory conditions. Gen. Hosp. Psychiatry. 2015; 37 (5): 399–407. DOI: 10.1016/j.genhosppsych.2015.05.002.
19. Lou P., Chen P., Zhang P. et al. Effects of smoking, depression, and anxiety on mortality in COPD patients: a prospective study. Respir. Care. 2014; 59 (1): 54–61. DOI: 10.4187/respcare.02487.
20. Tønnesen P. Smoking cessation and COPD. Eur. Respir. Rev. 2013; 22 (127): 37–43. DOI: 10.1183/09059180.00007212.
21. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307–316. DOI: 10.1586/17476348.1.3.307.
22. Avdeev S.N., Trushchenko N.V., Chikina S.Yu., Suvorova O.A. [Possibilities of erdostein therapy in reducing the frequency of exacerbations of chronic obstructive pulmonary disease]. Pul'monologiya. 2022; 32 (2): 253–259. DOI: 10.18093/0869-0189-2022-32-2-253-259 (in Russian).
23. Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017; 50 (4): 1700711. DOI: 10.1183/13993003.00711-2017.
24. IPCRG. Tsiligianni I., Hoines K., Jensen C. et al. Desktop helper No.10 – Rational use of inhaled medications for the patient with COPD and multiple comorbid conditions: Guidance for primary care. 2019. Available at: https://www.ipcrg.org/dth10 [Accessed: December 12, 2024].
Supplementary files
Review
For citations:
Budnevsky A.V., Avdeev S.N., Ovsyannikov E.S., Feigelman S.N. “COPD Navigator” – an innovative tool for doctor and patient. PULMONOLOGIYA. 2025;35(1):86-94. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-1-86-94
Views:
472
Email this article 